Sign Up Today and Learn More About Foresight Diagnostics Stock
Invest in or calculate the value of your shares in Foresight Diagnostics or other pre-IPO companies through EquityZen's platform.
Foresight Diagnostics Stock (FODI)
Foresight Diagnostics develops novel technology for detect cancers from a simple blood draw.
About Foresight Diagnostics Stock
Founded
2020
Headquarters
Denver, CO, US
Industries
Software, Artificial Intelligence, Data and Analytics
Foresight Diagnostics Press Mentions
Stay in the know about the latest news on Foresight Diagnostics
Foresight Diagnostics Launches PRECISE-HL Trial to Explore ctDNA-Based Therapy De-Escalation in Classical Hodgkin Lymphoma (cHL)
prnewswire • Mar 05, 2025
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia
prnewswire • Mar 01, 2025
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
globenewswire • Jan 10, 2025
Foresight Diagnostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
businesswire • Dec 18, 2024
Other news to note for December 6, 2024
bioworld • Dec 08, 2024
Foresight Diagnostics Management
Leadership team at Foresight Diagnostics
Chief Operations Officer
Sandra Close
Founder
Maximilian Diehn
Join now and verify your accreditation status to gain access to:
- Foresight Diagnostics Current Valuation
- Foresight Diagnostics Stock Price
- Foresight Diagnostics Management
- Available deals in Foresight Diagnostics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Foresight Diagnostics Cap Table and Funding History by Share Class and Liquidity Preferences
- Foresight Diagnostics Revenue and Financials
- Foresight Diagnostics Highlights
- Foresight Diagnostics Business Model
- Foresight Diagnostics Risk Factors
- Foresight Diagnostics Research Report from SACRA Research
Trading Foresight Diagnostics Stock
How to invest in Foresight Diagnostics stock?
Accredited investors can buy pre-IPO stock in companies like Foresight Diagnostics through EquityZen funds. These investments are made available by existing Foresight Diagnostics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Foresight Diagnostics stock?
Shareholders can sell their Foresight Diagnostics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
